DE69529473D1 - Gezielte t-lymfozyten - Google Patents

Gezielte t-lymfozyten

Info

Publication number
DE69529473D1
DE69529473D1 DE69529473T DE69529473T DE69529473D1 DE 69529473 D1 DE69529473 D1 DE 69529473D1 DE 69529473 T DE69529473 T DE 69529473T DE 69529473 T DE69529473 T DE 69529473T DE 69529473 D1 DE69529473 D1 DE 69529473D1
Authority
DE
Germany
Prior art keywords
lymphocytes
tcr
target cells
targeted
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69529473T
Other languages
English (en)
Other versions
DE69529473T2 (de
Inventor
Bradley Michael John Stringer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellFactors PLC
Original Assignee
CellFactors PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellFactors PLC filed Critical CellFactors PLC
Application granted granted Critical
Publication of DE69529473D1 publication Critical patent/DE69529473D1/de
Publication of DE69529473T2 publication Critical patent/DE69529473T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
DE69529473T 1994-11-16 1995-11-16 Gezielte t-lymfozyten Expired - Fee Related DE69529473T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423085A GB9423085D0 (en) 1994-11-16 1994-11-16 Targeted T lymphocytes
GB9423085 1994-11-16
PCT/GB1995/002691 WO1996015238A1 (en) 1994-11-16 1995-11-16 Targeted t lymphocytes

Publications (2)

Publication Number Publication Date
DE69529473D1 true DE69529473D1 (de) 2003-02-27
DE69529473T2 DE69529473T2 (de) 2004-01-08

Family

ID=10764464

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529473T Expired - Fee Related DE69529473T2 (de) 1994-11-16 1995-11-16 Gezielte t-lymfozyten

Country Status (16)

Country Link
EP (1) EP0792354B1 (de)
JP (1) JPH10511542A (de)
KR (1) KR970707280A (de)
AT (1) ATE231550T1 (de)
AU (1) AU687271B2 (de)
CA (1) CA2203934A1 (de)
CZ (1) CZ289455B6 (de)
DE (1) DE69529473T2 (de)
DK (1) DK0792354T3 (de)
ES (1) ES2191065T3 (de)
GB (1) GB9423085D0 (de)
HU (1) HUT77472A (de)
MX (1) MX9703535A (de)
NZ (1) NZ295418A (de)
PT (1) PT792354E (de)
WO (1) WO1996015238A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
EP1012259B1 (de) 1997-06-04 2009-09-30 Oxford Biomedica (UK) Limited Tumor gezielter Vektor
EP1242456B1 (de) 1999-11-18 2008-10-15 Oxford Biomedica (UK) Limited Scfv antikörper gegen krankheiten-assoziierte moleküle
US7741077B2 (en) 2001-12-22 2010-06-22 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
KR101130597B1 (ko) * 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
JP6164759B2 (ja) 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
ES2112838T5 (es) * 1989-07-19 2004-09-01 Connetics Corporation Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
WO1992012996A2 (en) * 1991-01-22 1992-08-06 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Also Published As

Publication number Publication date
EP0792354A1 (de) 1997-09-03
EP0792354B1 (de) 2003-01-22
HUT77472A (hu) 1998-05-28
AU3875495A (en) 1996-06-06
KR970707280A (ko) 1997-12-01
CA2203934A1 (en) 1996-05-23
CZ144297A3 (en) 1997-10-15
DE69529473T2 (de) 2004-01-08
MX9703535A (es) 1997-08-30
WO1996015238A1 (en) 1996-05-23
GB9423085D0 (en) 1995-01-04
NZ295418A (en) 2000-02-28
DK0792354T3 (da) 2003-05-19
PT792354E (pt) 2003-06-30
ATE231550T1 (de) 2003-02-15
ES2191065T3 (es) 2003-09-01
CZ289455B6 (cs) 2002-01-16
AU687271B2 (en) 1998-02-19
JPH10511542A (ja) 1998-11-10

Similar Documents

Publication Publication Date Title
ATE231550T1 (de) Gezielte t-lymfozyten
GB2102810B (en) Human interferon-related peptides antigens antibodies and process for preparing the same
BR9305482A (pt) Processo de evocar em um hospedeiro mamífero uma resposta imune protetora contra infecção por helicobacter, composição de vacina adequada para o tratamento de infecção por helicobacter, vacina, processo de proporcionar proteção passiva a um hospedeiro mamífero contra infecção por helicobacter, anticanticorpo monoclonal e linhagem celular
ZA97721B (en) Methods for retreatment of patients afflicted with hepatitis C using consensus interferon.
DE60032622D1 (de) Zusammensetzung und verfahren zur krebs-antigen-immuntherapie
SE9602819L (sv) Anordning för värmebehandling
DK184583A (da) Beskyttelseshjelm med fastholdelseskrave
ATE54827T1 (de) Material und verfahren fuer herpes simplex virusimpfung.
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
DK419283D0 (da) Alkoholsubstituerede amider, fremgangsmade til fremstilling heraf samt anvendelse ved fremstilling af stoebebare polyurethanelastomerer
ES499227A0 (es) Procedimiento para la determinacion de antigenos carcinoem- brionicos en el plasma humano
GB2264949B (en) Measles virus recombinant poxvirus vaccine
NO163039C (no) Monoklonale antistoffer som er reaktive med delte idiotyper paa humane antistoffer overfor naturlig forekommende dnafra pasienter med systemisk lupus erythematosus for anvendelse ved in vitro-diagnostisering av sle-antistoffer.
NO920331L (no) Biologisk preparat samt bruk derav
PT964697E (pt) Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
IT1242125B (it) Apparecchio di riscaldamento e riscaldatore per esso.
ATA112988A (de) Schutzvorrichtung fuer den einlaufspalt
DE68902481T2 (de) Vorrichtung fuer verstellbare stuehle.
IT8068619A0 (it) Procedimento e dispositivo per trattamento di articoli con materiale particellare particolarmente per la tenacizzazione di articoli di vetro
DE3850261T2 (de) Gen des hüllproteins des gurkenmosaikvirus.
ES2129353A1 (es) Sistema de montaje de placas de coccion.
FR2648712B1 (fr) Vaccin contre le virus de la leucemie bovine
LTIP1883A (en) The calf embryo lung cell culture for cutivation of bovine leukemia virus
ATE79297T1 (de) Heizvorrichtung fuer kohlepartikeln.
IT1214163B (it) Dispositivo per la levigatura di pezzi curvi.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CELLFACTORS PLC, NEWPORT, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee